Aim: To study the lipid profile of HIV/AIDS patients on antiretroviral therapy.

Materials and Methods: The present study was carried out in Department of Medicine, Shri B. M. Patil Hospital and Research Centre, Vijayapur, Karnataka. This study was conducted between December 2013 and June 2015.

Results: 120 patients are studied for period of 18 months. 66.7% patients have Hypercholesterolemia and 33.3% have in the normal range. 80% of the patients have HDL below the normal range and 20% have in the normal range. 70% of the patients have hypertriglyceridemia and 30% have within the normal range. 60% of patients have LDL in the abnormal range and 40% in the normal range. 5.8% of the patients have VLDL within abnormal range and 94.2% have it within the normal range. Males are more affected than females. The patients in the young age group are more affected than patients in the older group.

Keywords: HIV, LDL, HDL, antiretroviral drugs.

1. Introduction

The introduction of effective highly active antiretroviral therapy (HAART) in the mid 1990s lead to the marked reduction in the morbidity and mortality from human immunodeficiency virus (HIV) infection. Increasing life expectancy, an aging population, and high rates of smoking have lead to concerns of the health of HIV infected individuals in the long run. Metabolic effects of HIV infection such as hypertriglyceridemia are well defined and side effects of HAART such as dyslipidemia and were described soon after its introduction [1].

Initial concerns of the increased rates of myocardial infarction arising as a result of dyslipidemia in HIV infected patients on antiretroviral (ARV) have been confirmed by studies such as the D.A.D study, a large, multicohort study that showed association between exposure to antiretroviral therapy and increased risk of myocardial infarction[2].

Endothelial function is also found to be abnormal in HIV infected patients. Changes in platelet reactivity among HIV infected patients also reported and increased rates of insulin resistance and diabetes is a well described side effect of exposure to some of the ARV. All of these factors act in combination with dyslipidemia to increase overall cardiovascular risk of HIV infected patients on ARV [3]. Hence the “STUDY OF LIPID PROFILE IN HIV/AIDS PATIENTS ON ANTIRETROVIRAL THERAPY” is undertaken to know the magnitude of the problem, of progression and severity of disease, and guide to therapy particularly in resource limited settings.

2. Materials and methods

The present study was carried out in Department of Medicine, Shri B. M. Patil Hospital and Research Centre, Vijayapur, Karnataka. This study was conducted between December 2013 and June 2015. A predetermined pretested Performa is used to record the details of history, physical examination and investigations. Patients which were included in this study were diagnosed HIV positive as per NACO guidelines using three spot tests COOMBS AIDS, TRILINE, QUALPRO [4]. Patients with a history of cardiovascular diseases like congenital heart diseases and with type II Diabetes mellitus were excluded from this study.

3. Results

120 cases of HIV diagnosed by ELISA method, admitted in BLDEU’s Shri B M Patil Medical College and...
research centre, Vijayapur, during a period of 18 months from Nov 2013 to June 2015. Of the 120 cases 83 patients were male and remaining 37 were females. Among them 49 patients were in the age group of 20-35, 56 patients were in the age group 36-50, and 15 were in the 51-70 age group. Among the patients in the age group of 20-35, 71.4% have hypertriglyceridemia, 71.4% have hypercholesterolemia, and 85.7% have low levels of HDL. Male patients were more affected than females. Patients in the young age group were more affected than the patients in the older age groups. Patients in the age group of 51-70 were having maximum LDL-80%. Of the 120 cases, 70% of cases had hypertriglyceridemia and 30% were within the normal range (Table 1 and figure 1). 66.7% of patients have hypercholesterolemia and 33.3% have total cholesterol in the normal range (table 2 and figure 2). 80% of patients have HDL below the normal range and 20% have within the normal range. (Table 3 and figure 3). 60% of patients have LDL above the normal range and 40% have in the normal range (Table 4 and figure 4). 5.8% of patients have VLDL within the abnormal range and 94.2% patients have in the normal VLDL (Table 5 and figure 5).

**Table 1: TG Distribution**

| TG       | N  | Percent |
|----------|----|---------|
| Normal   | 36 | 30      |
| Abnormal | 84 | 70      |
| Total    | 120| 100     |

**Table 2: TC distribution**

| TC       | N  | Percent |
|----------|----|---------|
| Normal   | 40 | 33.3    |
| Abnormal | 80 | 66.7    |
| Total    | 120| 100     |

**Table 3: Distribution of HDL**

| HDL        | N  | Percent |
|------------|----|---------|
| Normal     | 24 | 20      |
| Abnormal   | 96 | 80      |
| Total      | 120| 100     |

**Table 4: Distribution of LDL**

| LDL        | N  | Percent |
|------------|----|---------|
| Normal     | 48 | 40      |
| Abnormal   | 72 | 60      |
| Total      | 120| 100     |
The prevalence of dyslipidemia in HIV patients on antiretroviral therapy is very high. Males are affected more than females. Patients in the young age group (25-35) are having maximum dyslipidemia. In the above age group the prevalence of hypertriglyceridemia is 71.4%, that of hypercholesterolemia is 71.4%, and that of low HDL is 85.7%. In similar studies conducted by Cavin Epi Bekolo etal the prevalence of hypertriglyceridemia is 52%, that of hypercholesterolemia is 66.7%, and that low HDL is 80%. In the same study maximum numbers of patients were in the younger age group (20-35), 49 patients were found in this age group [5]. Hypertriglyceridemia in patients on antiretroviral therapy is common among patients taking Protease inhibitors as they increase the hepatic triglyceride synthesis by increased expression of key enzymes involved in its synthesis. There is impaired uptake of triglycerides in the adipocytes which leads to increases in their levels [6]. Antiretroviral drugs are responsible for reduced expression of LDL receptors, thus reducing fat storage and increasing free fatty acid plasma levels [7]. NRTI class of drugs is associated with a worst lipid profile parameters. They cause increases in total cholesterol, triglycerides and LDL. Among that category of drugs Stavudine is the drug associated with severe dyslipidemia [8]. The presence of an atherogenic lipid profile in HIV patients on antiretroviral therapy makes these patients more susceptible to cardiovascular events. A longer duration of antiretroviral therapy is associated with greater chances of coronary artery stenosis due to dyslipidemia and due to the metabolic effects of HIV infection. This has lead to increased concerns of myocardial infarction in HIV patients [9]. The presence of dyslipidemia in young patients makes them susceptible to subclinical coronary atherosclerosis is a major concern as lack of suspicion of coronary artery disease makes them prone to sudden grave consequences[10]. The lack of an alternative to antiretroviral therapy makes it more difficult to protect and prevent these patients from dyslipidemia and thus future cardiac events. After initiation of antiretroviral therapy of fasting lipid profile is a must for HIV patients.

5. Conclusion

Significant dyslipidemia is present in HIV patients on antiretroviral therapy. The study has further strengthened the relation between existences of coronary artery diseases in patients on antiretroviral therapy. It will help to encourage further studies to evaluate the role of individual antiretroviral drugs in causing dyslipidemia and also make clinicians aware to evaluate patients for dyslipidemia once they are initiated on antiretroviral therapy.

References

[1] Grunfield C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
[2] Friis-Moller N, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
[3] Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral resistance and impaired oral glucose tolerance in HIV infected patients. AIDS 1998; 12: F167-73.
[4] Annual Report 2013- 2014 NACO[Internet].[place unknown]:2013. Available from :http://naco.gov.in/NACO/Quick_Links/Directory_of_HIV_Data/
[5] Cavin Epi Bekolo, Leonard Ewane, Basile Kollo et al. The lipid profile of HIV infected patients receiving antiretroviral therapy in a rural Cameroonian population.
[6] Lenhard J, Croom DK, Weiel J, Winegar D. HIV protease inhibitors stimulate triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000; 20:2625-9.
[7] Carr A, Samaras K, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients’ receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
[8] Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs Stavudine in combination therapy in antiretroviral naïve patients: a 3 year randomized trial. JAMA 2004; 292: 191-201.
[9] Kingsley LA, Cuervo- Rojas J, Munoz A, Palella FJ et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: Multicentre AIDS Cohort study. AIDS. 2008; 22: 1589-99[PMID: 18670218].
[10] Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.

Table 5: Percent Distribution of VLDL

| VLDL    | N  | Percent |
|---------|----|---------|
| Normal  | 113| 94.2    |
| Abnormal| 7  | 5.8     |
| Total   | 120| 100     |

Figure 5: Percent Distribution of VLDL